Abiraterone Acetate Tablet
Product Images NDC 60687-790

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Abiraterone Acetate (NDC 60687-790). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by American Health Packaging, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

250 mg Abiraterone Acetate Tablet Blister (250 mg Abiraterone Acetate Tablet Blister)

250 mg Abiraterone Acetate Tablet Blister (250 mg Abiraterone Acetate Tablet Blister)
This image shows multiple small printed labels for Abiraterone Acetate tablets, USP 250 mg by American Health Packaging. Each label includes product name, strength, human prescription drug designation, American Health Packaging address, barcode, space for expiration date and lot number, and the NDC number 60687-790-11. The labels are arranged in a grid format.*
FDA Label Image

250 mg Abiraterone Acetate Tablets Carton (250 mg Abiraterone Acetate Tablets Carton)

250 mg Abiraterone Acetate Tablets Carton (250 mg Abiraterone Acetate Tablets Carton)
Abiraterone Acetate Tablets USP 250 mg oral tablets, packaged with 30 tablets (3 x 10), labeled by American Health Packaging. The label includes dosage strength, NDC 60687-790-21, a barcode, storage instructions, warnings for pregnant women, and a note to see full prescribing information.*
FDA Label Image

Ahp79021

Ahp79021
Image of a white, oval-shaped oral tablet with the imprint AN65 on one side. This corresponds to Abiraterone Acetate 250 mg oral tablets, labeled by American Health Packaging.*
FDA Label Image

Figure 1: Kaplan-meier Overall Survival Curves In Cou-aa-301 (intent-to-treat Analysis) (Figure 1)

Figure 1: Kaplan-meier Overall Survival Curves In Cou-aa-301 (intent-to-treat Analysis) (Figure 1)
A survival curve chart comparing percentage survival over time in months for Abiraterone Acetate 250 mg tablets versus placebo. The x-axis represents time to death in months, the y-axis represents percentage survival, and two lines distinguish survival for Abiraterone Acetate and placebo groups. Sample sizes at various time points are noted below the x-axis.*
FDA Label Image

Figure 2: Kaplan Meier Overall Survival Curves In Cou-aa-302 (Figure 2)

Figure 2: Kaplan Meier Overall Survival Curves In Cou-aa-302 (Figure 2)
A survival curve chart comparing the percentage of subjects without death over 60 months from randomization between Abiraterone Acetate and placebo groups. The x-axis shows months from randomization (0 to 60), and the y-axis shows the percentage of subjects alive (0% to 100%). Two lines represent the survival trends for each group over time.*
FDA Label Image

Figure 3: Kaplan Meier Curves Of Radiographic Progression-free Survival In Cou-aa-302 (intent-to-treat Analysis) (Figure 3)

Figure 3: Kaplan Meier Curves Of Radiographic Progression-free Survival In Cou-aa-302 (intent-to-treat Analysis) (Figure 3)
A Kaplan-Meier survival curve showing the percentage of subjects without radiographic progression or death over months from randomization. The graph compares Abiraterone Acetate and placebo groups, with corresponding numbers at risk listed below the x-axis at various time points up to 18 months.*
FDA Label Image

Figure 4: Kaplan-meier Plot Of Overall Survival; Intent-to-treat Population In Latitude Updated Analysis (Figure 4)

Figure 4: Kaplan-meier Plot Of Overall Survival; Intent-to-treat Population In Latitude Updated Analysis (Figure 4)
A survival curve chart comparing the percentage of subjects without death over time (months from randomization) for Abiraterone acetate versus Placebo. The x-axis shows months from 0 to 72, and the y-axis shows percent survival from 0 to 100%. A table below lists the number of subjects at risk at various time points for both treatment groups.*
FDA Label Image

Structural Formula (Structural Formula)

Structural Formula (Structural Formula)
Chemical structure diagram of Abiraterone, the active ingredient in Abiraterone Acetate tablets.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.